



FY27 Appropriations Cheat Sheet: Global Tuberculosis

## **FY27 NSRP/SFOPS programmatic request: Tuberculosis**

**Bill:** State, Foreign Operations, and Related Programs (Senate SFOPS) / National Security, Department of State, and Related Programs (House NSRP)

**Agency:** State

**Account:** Global Health

**Subject/Sector:** Tuberculosis

**Type of request:** Funding/Programmatic

**Your suggested FY27 level request:** ***\$1 billion, of which no less than \$15 million for the Global Drug Facility.***

**FY27 President's Budget Request:** TBD

**FY26 enacted level:** \$378.7 million

**FY26 House level:** \$394.5 million

**FY26 Senate level:** \$378.7 million

**FY25 enacted level:** \$394.5 million

**FY24 enacted level:** \$394.5 million

### **Rationale/Justification:**

Investments in fighting tuberculosis (TB) globally is imperative for keeping Americans everywhere safer and healthier. While TB is often thought of as a disease of the past, it is the world's leading infectious killer. It is an airborne contagion, and the elderly, pregnant people, children, those with diabetes, HIV/AIDS, and other immuno-compromising factors mean you are more at risk for developing an active case of TB. It is rightly a top priority in the new America First Global Health Strategy.

With U.S. leadership over the past two decades, we've made progress in the fight against TB. New innovations have dramatically shortened TB treatment, reduced side effects, and saved more lives. In U.S.-supported countries, TB-related deaths have been reduced by roughly 50 percent since 2000, saving over 75 million lives. This progress against infectious diseases keeps us all safe and increases economic stability around the world.

A strong commitment from Congress in FY27 can:

- **Support countries to save lives** and expand prevention and treatment for all forms of TB.
- **Scale up game-changing new innovations**, including those developed here in the United States, to drive down costs and save more lives. Powerful new tools like mobile x rays for screening, AI-enabled diagnosis, faster & more tolerable treatment regimens, and more are ready to scale up.
- **Increase funding that goes directly to local partners**, promoting sustainability through locally-driven, country-owned health systems.
- **Ensure countries receive the highest quality, lowest priced tests and drugs** by pooling resources through the Global Drug Facility.

The Global Drug Facility (GDF) is the world's most powerful tool for securing affordable, quality tools in the fight against TB. By pooling demand across countries, the GDF secures the most affordable prices and ensures quality. Between 2015 and 2024, GDF achieved remarkable price reductions of up to 98% for more than 25 key medicines used to treat drug-resistant TB. These cost reductions have saved millions of dollars for donors like the United States, and made it easier for countries to transition away from donor financing, with dozens of countries now procuring their own products directly through the GDF.

**Additional Information:** <https://results.org/wp-content/uploads/FY27-Global-Tuberculosis-Appropriations-Memo.pdf>